Agenda - Council Work Session - 04/11/2023

Home

APPENDIX Repealed Minnesota Statutes: HO100-9 (4) Tourette's syndrome; (5) amyotrophic lateral sclerosis; (6) seizures, including those characteristic of epilepsy; (7) severe and persistent muscle spasms, including those characteristic of multiple sclerosis; (8) inflammatory bowel disease, including Crohn's disease; (9) terminal illness, with a probable life expectancy of under one year, if the illness or its treatment produces one or more of the following: (i) severe or chronic pain; (ii) nausea or severe vomiting; or (iii) cachexia or severe wasting; or (10) any other medical condition or its treatment approved by the commissioner. 152.23 LIMITATIONS. (a) Nothing in sections 152.22 to 152.37 permits any person to engage in and does not prevent the imposition of any civil, criminal, or other penalties for: (1) undertaking any task under the influence of medical cannabis that would constitute negligence or professional malpractice; (2) possessing or engaging in the use of medical cannabis: (i) on a school bus or van; (ii) on the grounds of any preschool or primary or secondary school; (iii) in any correctional facility; or (iv) on the grounds of any child care facility or home day care; (3) vaporizing or combusting medical cannabis pursuant to section 152.22, subdivision 6: (i) on any form of public transportation; (ii) where the vapor would be inhaled by a nonpatient minor child or where the smoke would be inhaled by a minor child; or (iii) in any public place, including any indoor or outdoor area used by or open to the general public or a place of employment as defined under section 144.413, subdivision lb; and (4) operating, navigating, or being in actual physical control of any motor vehicle, aircraft, train, or motorboat, or working on transportation property, equipment, or facilities while under the influence of medical cannabis. (b) Nothing in sections 152.22 to 152.37 require the medical assistance and MinnesotaCare programs to reimburse an enrollee or a provider for costs associated with the medical use of cannabis. Medical assistance and MinnesotaCare shall continue to provide coverage for all services related to treatment of an enrollee's qualifying medical condition if the service is covered under chapter 256B or 256L. 152.24 FEDERALLY APPROVED CLINICAL TRIALS. The commissioner may prohibit enrollment of a patient in the registry program if the patient is simultaneously enrolled in a federally approved clinical trial for the treatment of a qualifying medical condition with medical cannabis. The commissioner shall provide information to all patients enrolled in the registry program on the existence of federally approved clinical trials for the treatment of the patient's qualifying medical condition with medical cannabis as an alternative to enrollment in the patient registry program. 152.25 COMMISSIONER DUTIES. Subdivision 1. Medical cannabis manufacturer registration. (a) The commissioner shall register two in -state manufacturers for the production of all medical cannabis within the state. A registration agreement between the commissioner and a manufacturer is nontransferable. The commissioner shall register new manufacturers or reregister the existing manufacturers by December 7R